
    
      This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety,
      tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD),
      pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an
      anti-CD47 antibody, in subjects with advanced relapsed or refractory solid tumors and
      lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose
      escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with
      pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.
    
  